Dr Nicholas Jonhson, new Chief Medical Advisor
August 2020: After closing a funding round of €4.25 million, ARTHEx confirms the professionalization of its team with the appointment of Nicholas Johnson, M.D., M.Sci., FAAN, as the Chief Medical Advisor of the company. Dr. Johnson is a physician specialist in DM1, associate professor of Neurology and Human and Molecular Genetics, vice chair of research … Read more
Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology
Funding will help advance development of company’s Myotonic Dystrophy therapy Valencia and Barcelona, Spain, and Paris, France, July 23, 2020 – Arthex Biotech (ARTHEx), a preclinical stage life sciences company focused on the development of the next generation antisense RNA therapies for the treatment of Myotonic Dystrophy Type 1 (DM1), today announces it has closed … Read more
International Myotonic Dystrophy Consortium
June 2019: The ARTHEx Biotech team at the International Myotonic Dystrophy Consortium held from 10 to 14 June 2019 in Gothenburg, Sweden. “Challenges in Myotonic Dystrophy – from basic science to therapy”.
J.P. MORGAN
January 2019: ARTHEx S.L. participation at the 37th Annual J.P. Morgan Healthcare Conference, celebrated from January 7 to 10 2019 in San Francisco, California.
BIO International Convention
June 2018: ARTHEx S.L. participation at the BIO International Convention, the most important partnering meeting of the international biotechnology sector, which took place from June 4 to 7 2018 in Boston, Massachusetts.